



SPARC/Sec/SE/2021-22/020

2nd June 2021

To
BSE Limited
P J Towers,
Dalal street,
Mumbai - 400001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Sub: Disclosure of Related Party Transactions – March 2021

Dear Sir/ Madam,

In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, we hereby submit the Related Party Transactions on consolidated basis, in accordance with the applicable accounting standards, for the half year ended 31st March 2021.

This is for your information and record.

Thanking you,

Yours faithfully,

For Sun Pharma Advanced Research Company Limited

Debashis Dey
Company Secretary

Encl: As above.

Indian Accounting Standard (Ind AS-24) " Related Party Disclosures "

Names of related parties and description of relationship

1. Key Management Personnel

Dilip S. Shanghvi	Chairman & Managing Director
Sudhir V. Valia	Non Executive Director
Rajamannar Tennati	Non-Executive Director
Bhavna Doshi	Independent Director
Ferzaan Engineer	Independent Director
Robert Jay Spiegel	Independent Director (w.e.f. 1st June 2020)

2. Holding Company

Shanghvi Finance Private Limited

3. Enterprise under Significant Influence of Key Management Personnel (with whom transactions are entered during the year ended March 31, 2021)

Dusa Pharmaceuticals Inc.	Sun Pharmaceutical Industries Europe BV
Insite Vision Inc.*	Sun Pharmaceutical Industries Inc.
OHM Laboratories Inc.	Sun Pharmaceutical Industries Limited
Sun Pharma Global FZE	Taro Pharmaceuticals Industries Limited
Sun Pharma Laboratories Limited	

* Insite Vision Inc. has been merged with Sun Pharmaceutical Industries Inc. w.e.f. April 01, 2020.

₹ In Lakhs

Particulars	Half Year ended March 31, 2021
Director Sitting Fees	
Sudhir V. Valia	2.70
Rajamannar Tennati	1.20
Bhavna Doshi	3.00
Ferzaan Engineer	3.00
Robert Jay Spiegel	3.00
Shanghvi Finance Private Limited	
Loan received	13,000.00
Loan repayment	15,000.00
Interest paid	411.77
Corporate guarantee received	20,000.00
Dusa Pharmaceuticals Inc.	
Sale of services - R&D services	5.43
OHM Laboratories Inc.	
Sale of services - R&D services	3.07
Purchase of goods	11.87
Sun Pharma Global FZE	
Sale of services - License fees / Royalty / R&D services	532.57
Sun Pharma Laboratories Limited	
Sale of services - License fees / Royalty / R&D services	1,998.84
Purchase of goods	0.74

₹ In Lakhs

Particulars	Half Year ended March 31, 2021
Sun Pharmaceutical Industries Europe BV	
Purchase of goods	6.76
Sun Pharmaceutical Industries Inc.	
Sale of services - R&D services	11.13
Purchase of Services - R&D services	1,074.57
Reimbursement of expenses paid	101.92
Purchase of goods	19.81
Sun Pharmaceutical Industries Limited	
Sale of services - License fees / Royalty / R&D services	2,174.32
Sale of property, plant & equipment	446.76
Purchase of goods	255.65
Purchase of property, plant & equipment	116.58
Rent expenses	101.59
Purchase of Services - R&D services	328.45
Reimbursement of expenses paid	85.80
Reimbursement of expenses received	15.33
Taro Pharmaceuticals Industries Limited	
Sale of services - R&D services	3.65

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED**Balance outstanding - Receivable / (Payable)**

₹ In Lakhs

Particulars	As at March 31, 2021
Robert Jay Spiegel	(1.25)
Sudhir V. Valia	(0.28)
Shanghvi Finance Private Limited	(8,094.70)
Dusa Pharmaceuticals Inc.	5.43
Insite Vision	(0.95)
OHM Laboratories Inc.	(8.77)
Sun Pharma Global FZE	357.66
Sun Pharma Laboratories Limited	1,108.11
Sun Pharmaceutical Industries Europe BV	(13.15)
Sun Pharmaceutical Industries Inc.	(3,672.49)
Sun Pharmaceutical Industries Limited	(118.90)
Taro Pharmaceuticals Industries Limited	0.88

* The Company has an outstanding corporate guarantee from Shanghvi Finance Private Limited amounting to ₹ 20,000 Lakhs (Previous year : NIL) as at March 31, 2021.

Chetan M. Rajpara
Chief Financial Officer